A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

NCT06143956 · Recruiting

Last updated 2026-05-28

This clinical trial is testing different weight-loss treatments in adults who are overweight or have obesity to see which approaches are studied.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind screening study

Participants 1,481 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2023-11 · est. completion 2028-02

Where 53 sites · Argentina, United States

What this study is testing ClinicalTrials.gov NCT06143956 ↗

Description as written by the study sponsor.

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.

Treatments tested

LY3305677 Drug

Administered SC. ISA specific interventions will be listed in the ISA.
LY3841136 also known as Eloralintide Drug

Administered SC. ISA specific interventions will be listed in the ISA.
Tirzepatide also known as LY3298176 Drug

Administered SC. ISA specific interventions will be listed in the ISA.
LY3549492 Drug

Administered orally. ISA specific interventions will be listed in the ISA.
LY3532226 also known as Macupatide Drug

Administered SC. ISA specific interventions will be listed in the ISA.
Placebo Drug

Administered SC. ISA specific interventions will be listed in the ISA.
Placebo Drug

Administered orally. ISA specific interventions will be listed in the ISA.

Main thing measured	Number of Participants Allocated to Each ISA
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06143956 ↗